Enfortumab vedotin is an advanced targeted therapy drug that is used for the treatment of Locally Advanced or Metastatic Urothelial Carcinoma. This is an FDA approved drug with unique mechanism of action that targets Nectin-4 antigen. This is considered to be novel and first of its kind to target the cancer cells through such mechanism. Padcev is the brand name and it is now commercially available. Enfortumab in India is considered as a treatment option by the top rated Oncologists. It can be procured for specific patients based on the expert recommendations.

Enfortumab is also considered to be a promising treatment for bladder cancer management. More data can point towards the possibility of expanding the indications in cancer care. It is an antibody drug conjugate, a classification under anticancer agents. This has been given the breakthrough therapy status. It contains anti-Nectin-4 monoclonal antibody that is effective in targeting Nectin-4 on the cell surfaces, especially targeting the cancer cell. Being a targeted therapy, the chances of affecting the normal cell would be less while the drug specifically targets the cancer cells.

Padcev in India can be sourced from the European countries. It is jointly developed by Seattle Genetics and Astellas Pharma. It had received accelerated approval from FDA in 2019. Data suggests that the patients who received PD-1/PD-L1 inhibitor prior to Enfortumab have shown promising responses. This is certainly considered as a durable option for treating locally advanced or metastatic urothelial
cancer.